Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan PLC

www.allergan.com

Latest From Allergan PLC

Finance Watch: A Bountiful November Harvest For Venture-Backed Biopharma

Five funds raised more than $1bn to back biotech firms; Arcus leads recent VC rounds with $107m GV-backed Series C; Celgene, Valeant sell notes to retire debt; and Alnylam cashes in on investor goodwill.

Financing Business Strategies

Will J&J TRANSFORM Esketamine Into A Viable Depression Treatment?

In early 2018 Johnson & Johnson is expecting to announce the first data from its long-awaited pivotal clinical trial program for esketamine in treatment-resistant depression; a successful result will open a lucrative commercial opportunity for J&J and give the wider depression market a new direction for growth.

Scrip 100 Neurology

Samsung's Ontruzant Becomes First Trastuzumab Biosimilar Approved In EU

Samsung Bioepis is poised to grab the leading position in the trastuzumab biosimilar market in Europe as its biosimilar Ontruzant gets the European Commission's approval ahead of the competition.

Biosimilars EU

Will Inter Partes Review Go Away? Supreme Court Weighs Fate

Biopharma and generic industries stand on opposing sides in case that could eliminate the patent challenge proceeding. Interactive timeline covers IPR's five-year history leading to oral arguments Nov. 27.

Legal Issues Intellectual Property
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register